Drug Profile
Research programme: small interfering RNA prodrug therapeutics - BianoScience
Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator BianoScience
- Class Antineoplastics; Peptides; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in Germany (Parenteral)
- 15 Sep 2017 Preclinical trials in Triple negative Breast cancer in Germany (Parenteral) before September 2017 (BianoScience pipeline, September 2017)
- 15 Sep 2017 BianoScience plans a phase I/IIa trial for Breast cancer (BianoScience pipeline, September 2017)